Navigation Links
Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
Date:2/4/2008

ROCKVILLE, Md., Feb. 4 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that its presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference will be webcast and may be accessed at http://www.hgsi.com

(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )

A member of Human Genome Sciences' senior management team will present an overview of the company on Wednesday, February 6, 2008 at 2:20 pm Eastern Time.

Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at http://www.hgsi.com.


'/>"/>
SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Stemagen First to Create Cloned Human Embryos From Adult Cells
2. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
3. International team identifies 480 genes that control human cell division
4. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JPMorgan Conference
5. Department of Health & Human Services Names Dr. Eric Rose to National Biodefense Science Board
6. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
7. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
8. Human Genome Sciences to Sponsor Conference Call
9. Lethal Human H5N1 Influenza Virus Replikin Gene Still Upregulated
10. The closest look ever at native human tissue
11. International Human Rights Day Recognized by Terasem Movement, Inc.s Third Annual Colloquium on the Law of Transbeman Persons
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4